Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.79 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.79 |
| ▸ | RET | P07949 | 6/20 | 0.79 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.79 |
| ▸ | KIT | P10721 | 3/20 | 0.79 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.79 |
| ▸ | FLT1 | P17948 | 2/20 | 0.79 |
| ▸ | FLT4 | P35916 | 2/20 | 0.79 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.79 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.79 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.79 |
| ▸ | ERN1 | O75460 | 1/20 | 0.79 |
| ▸ | STK10 | O94804 | 1/20 | 0.79 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.79 |
| ▸ | ESR1 | P03372 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | BCR | P11274 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20927261 | 0.97 | FGFR4 (0.85) | KDRFGFR4RETPDGFRAPDGFRB | |
| SCHEMBL20927342 | 0.93 | FGFR4 (0.76) | KDRFGFR4RETPDGFRAPDGFRB | |
| SCHEMBL20927323 | 0.91 | FGFR4 (0.73) | KDRFGFR4RETPDGFRAPDGFRB | |
| SCHEMBL19956957 | 0.91 | KDR (0.79) | KDRFGFR4RETPDGFRAPDGFRB | |
| SCHEMBL20927411 | 0.90 | FGFR4 (0.73) | KDRFGFR4RETPDGFRAPDGFRB | |
| SCHEMBL20927355 | 0.90 | FGFR4 (0.71) | KDRFGFR4RETPDGFRAPDGFRB | |
| SCHEMBL20927336 | 0.90 | FGFR4 (0.72) | KDRFGFR4RETPDGFRAPDGFRB | |
| Lenvatinib SCHEMBL29349806 | 0.89 | FGFR4 (1.00) | KDRFGFR4RETPDGFRAPDGFRB | |
| Lenvatinib SCHEMBL29372021 | 0.89 | FGFR4 (1.00) | KDRFGFR4RETPDGFRAPDGFRB | |
| Lenvatinib SCHEMBL864638 | 0.89 | FGFR4 (1.00) | KDRFGFR4RETPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | KDR 150/4885FGFR4 146/4885RET 19/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | KDR 150/4885FGFR4 146/4885RET 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.